转移性结直肠癌治疗的新进展.pptVIP

*OS,overallsurvival;PFS,progression-freesurvival.****ECOG,EasternCooperativeOncologyGroup;mCRC,metastaticcolorectalcancer;PS,performancescore;q3w,every3weeks.***Bev,bevacizumab;ITT,intentiontotreat;XELOX,capecitabine,oxaliplatin.*CR,completeresponse;FOLFIRI,leucovorin/fluorouracil/irinotecan;mCRC,metastaticcolorectalcancer;PR,partialresponse;SD,stabledisease.**OS,overallsurvival;PFS,progression-freesurvival.**5-FU,5-fluorouracil;ECOG,EasternCooperativeOncologyGroup;FOLFOX4,5-fluorouracil,oxaliplatin,leucovorin;IV,intravenously;LV,leucovorin;mCRC,metastaticcolorectalcancer;q2w,every2weeks;XRT,external-beamradiotherapy.VELOUR研究:生存结果VanCutsemE,etal.JClinOncol.2012;30:3499-3506.OS(%)100806040200Mos036912151821242730333639StratifiedHR:0.817(95.34%CI:0.713-0.937;log-rankP=.0032)Placebo/FOLFIRI

Median:12.06mosAflibercept/FOLFIRI

Median:13.50mosPFS(%)100806040200Mos036912151821242730StratifiedHR:0.758(95%CI:0.661-0.869;log-rankP.0001)Placebo/FOLFIRI

Median:4.67mosAflibercept/FOLFIRI

Median:6.90mos(阿帕西普)(阿帕西普)第62页，共69页，星期日，2025年，2月5日VELOUR研究:按贝伐单抗分层OSTaberneroJ,etal.EurJCancer.2013;[Epubaheadofprint].OS(%)100806040200Mos036912151821242730333639HR:0.862(95.34%CI:0.673-1.104)Placebo/FOLFIRI

Median:11.7mosAflibercept/FOLFIRI

Median:12.5mosPtsatRisk,n

Placebo

AFL187

186170

178138

150115

12181

8954

5937

3622

2213

13PreviousBevacizumabOS(%)100806040200Mos036912151821242730333639HR:0.788(95.34%CI:0.699-0.927)Placebo/FOLFIRI

Median:12.4mosAflibercept/FOLFIRI

Median:13.9mosPtsatRisk,n

Placebo

AFL427

426403

388347